SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Ella Fitzgerald — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElla Fitzgerald
Date of birth1917-04-25
IdentifiersMRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640
Document date1987-05-26
AuthorOdessa Whitlow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of the new glucose plan, seen the same day by vascular surgery. [S]

History of Present Illness

Ms. Fitzgerald returns two weeks after her first visit and is seen by Dr. Okafor-Lane of vascular surgery on the same day. She stopped glipizide, moved glargine 24 units to the morning, and started empagliflozin 10 mg and atorvastatin 80 mg. Her continuous glucose monitor shows glucose between 70 and 180 mg/dL 58% of the time, time below 70 mg/dL 0.5%, with a lowest reading of 68 mg/dL after a long rehearsal, and no reading below 54 mg/dL; there have been no lows after shows. She has no burning or itching with urination and no muscle aches. Calf cramping still stops her after about one and a half blocks, more on the right; she has no rest pain or sores. Her right eye remains blurred; the retina clinic will see her next week. [S]

ElementDetail
GlucoseTime in range 58%; time below 70 mg/dL 0.5%; lowest 68 mg/dL; none below 54
MedicinesGlipizide stopped; glargine 24 units each morning; empagliflozin and atorvastatin 80 mg started, no side effects
ClaudicationCalf pain after about one and a half blocks; no rest pain
EyesRetina clinic appointment next week

Review of Systems

SystemResultFinding
CardiovascularPositiveCalf cramping on walking; no chest pain, rest pain, or ankle swelling
EyesPositiveRight-eye blur unchanged
GenitourinaryNegativeNo burning, itching, or discharge
MusculoskeletalNegativeNo muscle aches on the higher statin dose
IntegumentaryNegativeNo foot sores or blisters

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with breakfast and the evening mealOral route1977-03-01activeS
Glipizide 10 mg oral tablet, one tablet by mouth twice daily before mealsOne tablet by mouth twice daily before breakfast and the evening mealOral route1982-09-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime30 units at bedtimeSubcutaneous route1984-04-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 24 units under the skin each morning24 units each morning, at the same clock time on tour, with written time-zone adjustmentsSubcutaneous route1987-05-11activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02 to 1987-05-11completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1987-05-11activeS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgeryOral route1987-05-11activeS
Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucoseOne spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911Nasal route1987-05-11activeS
Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mgOne tablet by mouth twice daily, with aspirin 81 mg once dailyOral route1987-05-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1987-05-26Body height165cmS
1987-05-26Body weight83.8kgS
1987-05-26Body mass index (BMI) [Ratio]30.8kg/m2S
1987-05-26Systolic blood pressure124mm[Hg]S
1987-05-26Diastolic blood pressure70mm[Hg]S
1987-05-26Heart rate60/minS
1987-05-26Respiratory rate16/minS
1987-05-26Body temperature36.5CelS
1987-05-26Oxygen saturation in Arterial blood by Pulse oximetry97%S

Physical Exam

Vital signs recorded on 1987-05-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 83.8 kg; blood pressure 124/70, pulse 60
FeetSkin intact; calluses under the second metatarsal heads; hammer toes of the second and third toes; no ulcer; monofilament felt at all sites; feet warm with slow capillary refill on the right
VascularFemoral pulses present; popliteal and foot pulses absent on the right; foot pulses faint on the left

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complicationsactiveconfirmed E11.51S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.
Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problemsactiveconfirmed E11.3311S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.
Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgeryactiveconfirmed I25.10S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHemoglobin A1cEvery three months when not at goal or after a change; every six months at goalUp to date8.6% two weeks ago; next at three months
Medication safetyContinuous glucose monitor review: time in range and time below rangeEvery visitCompleted todayTime in range 58%; time below 70 mg/dL 0.5%; none below 54 mg/dL
Medication safetyHypoglycemia events, show-day plan, and glucagonEvery visitCompleted todayNo lows after shows; lowest 68 mg/dL after a long rehearsal; glucagon carried; road manager trained
Medication safetyEmpagliflozin safety: genital infection, volume, and sick-day rulesAt the start and every visitCompleted todayNo genital symptoms; sick-day rules reviewed for travel days
LaboratoryCreatinine, eGFR, and potassiumWithin three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban reviewUp to dateCreatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L two weeks ago; next at three months
LaboratoryLipid panel4 to 12 weeks after a statin or other lipid-lowering change, then yearlyDueAtorvastatin raised to 80 mg two weeks ago; lipid panel due 4 to 12 weeks after the change
ExaminationFoot inspection, protective sensation, and pulsesEvery visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six monthsCompleted todayNo ulcer; protective sensation intact; calluses and hammer toes; podiatry appointment within three weeks
ImagingAnkle-brachial and toe-brachial indicesAt diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptomsUp to dateAnkle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55 at intake; arterial duplex by vascular surgery today
ExaminationWalking distance and claudication symptomsEvery visitCompleted todayCalf pain after about one and a half blocks; no rest pain
ReferralVascular surgery consultationPromptly for claudication with an abnormal ankle-brachial indexCompleted todaySeen by Dr. Okafor-Lane today
Self-managementSupervised exercise therapyThree times a week for twelve weeksOrderedHospital program starts next week; home walking plan for tour weeks
ReferralRetinal examination and visual acuityWith each retina-clinic treatment while macular edema is treated; at least yearly in both eyesOrderedRetina clinic next week for the right macular edema
ExaminationBlood pressureEvery visitCompleted today124/70 mmHg, at goal below 130/80
ExaminationWeight and BMIEvery visitCompleted today83.8 kg
Medication safetyBleeding on rivaroxaban and aspirinAt the start and every visitCompleted todayStarting today; no bleeding history; no anti-inflammatory painkillers
Self-managementAccess and equity: tour-date scheduling, video visits, large print, drug costsEvery visitCompleted todayVisits set around tour dates; large-print plan given; rivaroxaban cost checked with her Part D plan

Goal progress:

Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026)

Follow-up: Supervised exercise from next week. Retina clinic next week. Podiatry within three weeks. Annual wellness visit in three weeks. Three-month review with A1c, lipids, and kidney tests. Next scheduled visit 1987-06-15: subsequent annual wellness visit. [S]